LCC2人乳腺癌Tamoxifen耐药株cell line细胞株 BioVector NTCC质粒载体菌种细胞基因保藏中心

LCC2人乳腺癌Tamoxifen耐药株cell line细胞株


Comments  Population: Caucasian.
Selected for resistance to: ChEBI; CHEBI:44616; Afimoxifene (4-hydroxytamoxifen; 4-OH TAM).
Omics: Proteome analysis.
Sequence variations  Homozygous for CDKN2A deletion (from parent cell line).
Heterozygous for GATA3 p.Asp336Glyfs*17 (c.1006dupG) (from parent cell line).
Heterozygous for PIK3CA p.Glu545Lys (c.1633G>A) (ClinVar=VCV000013655) (from parent cell line).
Disease  Invasive ductal carcinoma, not otherwise specified (NCIt: C4194)
Derived from metastatic site: Pleural effusion.
Species of origin  Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy  Parent:  (MCF7/LCC1)
Sex of cell  Female
Age at sampling  69Y
Category  Cancer cell line

Publications
PubMed=8324732
Brunner N., Frandsen T.L., Holst-Hansen C., Bei M., Thompson E.W., Wakeling A.E., Lippman M.E., Clarke R.
MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780.
Cancer Res. 53:3229-3232(1993)

Growth Medium: 5% CCS-IMEM containing 10-12M to 10-6 M 4OH-TAM

Supplier来源:BioVector NTCC Inc.
TEL电话:+86-010-53513060
Website网址: http://www.biovector.net